Welcome to our dedicated page for Barrick Mining news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining stock.
Barrick Mining Corporation reports developments tied to its global gold and copper mining, exploration and development portfolio. Company news commonly covers operating and financial results, mine and project updates, technical and governance matters, and capital allocation actions for common shares that trade on the NYSE under B and on the TSX under ABX.
Recurring updates include quarterly results releases, dividend declarations, share repurchase authorizations, annual meeting materials and changes in executive or board oversight. Barrick also reports on its gold assets in North America and other mining jurisdictions, including disclosures connected to major mines, development projects, reserves, production, costs, cash flow and responsible mining obligations.
Crawford & Company (NYSE: CRD-A, CRD-B) announced that its Board of Directors approved an increase in the quarterly dividend from $0.075 to $0.08 per share for both Class A and Class B common stock. The dividend will be paid on August 24, 2026 to shareholders of record as of the close of business on August 14, 2026.
BioArctic (Nasdaq Stockholm: BIOA B)/b) reports that partner recorded preliminary global Leqembi sales of JPY 29.3 billion in the second quarter 2026. This generated a royalty to BioArctic of SEK 179 million, about 10% higher than the royalty for Q2 2025.
According to BioArctic, Q2 2025 royalty included a one-time Chinese stockpiling effect of around JPY 5.3 billion; excluding this, Q2 2026 royalty grew about 43% year-on-year. BioArctic’s full Q2 2026 report is scheduled for August 26, 2026. Leqembi is approved in 53 countries, with IV maintenance dosing approved in 8 countries and subcutaneous formulations progressing through regulatory processes in the US, Japan and China.
Crawford & Company (NYSE: CRD-A, CRD-B) has released a report titled “Super El Niño – Potential Impacts for Agriculture in the UK,” outlining how a particularly strong El Niño could increase weather-related risks for UK farmers and agricultural insurers.
According to Crawford & Company, heavier rainfall, flooding, storms and compound events of drought followed by flooding could raise insured losses, complicate claims and lengthen loss tails. The report also notes potential secondary effects such as crop establishment problems, soil erosion, higher feed and input costs, greater livestock disease pressures and increased claims complexity, reinforcing the need for resilience measures and proactive risk management by both farmers and insurers.
Crawford & Company announced that Matthew Solorio, a national general adjuster in its Global Technical Services division, has been named to Insurance Business America’s 2026 Rising Stars list, which honors leading U.S. insurance professionals under 40 for technical expertise, leadership and innovation.
Solorio manages complex, often multimillion-dollar commercial and residential property claims nationwide, coordinating multidisciplinary teams to resolve large-loss, catastrophe and technical claims. He also co-leads initiatives to improve claims workflows and operational efficiency, exemplifying Crawford’s depth of technical talent in complex claims handling.
Barrick Mining Corporation (NYSE:B)(TSX:ABX) agreed to subscribe for 15,470,934 units of Kingfisher Metals in a non-brokered private placement at C$1.35 per unit, for total consideration of about C$20.9 million. Each unit includes one common share and one-half warrant, with each whole warrant exercisable at C$1.70 for two years.
After closing, Barrick will own about 9.9% of Kingfisher on a non-diluted basis and 14.1% on a partially diluted basis, assuming warrant exercise. An investor rights agreement grants Barrick anti-dilution and information rights tied to Kingfisher’s Highway 37 Project in British Columbia.
For two years from closing, Kingfisher will face restrictions on selling or transferring interests in Highway 37 without Barrick’s consent, subject to exceptions. Barrick will be subject to a standstill capping ownership at 15% (up to 19.9% if a third party exceeds 10%), an 18‑month lockup on its shares, and voting or abstention commitments. Barrick and Kingfisher will form a technical committee, and Barrick may provide technical support for the 2027 and 2028 drilling seasons. Barrick describes the purchase as being for investment purposes and may adjust its holdings based on market conditions.
BioArctic (Nasdaq Stockholm: BIOA B) reported that partner Eisai presented interim real-world data from the three-year LEADER study of Leqembi in early Alzheimer's disease at AAIC 2026. Among 427 evaluable patients treated for an average of 17 months (mean 520 days, 26 doses), 82.5% remained stable or improved in disease stage, with 75.9% stable and 6.6% improving from mild AD dementia to MCI due to AD. Results were consistent across sex, race, ethnicity and APOE genotype, and nearly 87% of patients chose to remain on treatment.
In 155 patients on once-every-four-weeks IV maintenance, about 81% were stable or improved, while 12 of 14 on weekly SC maintenance maintained stage. Overall safety was described as consistent with the US FDA-approved label; ARIA occurred in 12.3% of patients, mostly asymptomatic and mild, with no new ARIA-E events, macrohemorrhages or intracerebral hemorrhages >1 cm during IV maintenance.
BioArctic (Nasdaq Stockholm: BIOA B) reports that partner Eisai has received FDA approval for a supplemental Biologics License Application for once-weekly subcutaneous Leqembi Iqlik (lecanemab-irmb) as a starting dose for treating early Alzheimer's disease in US adults. The US launch is planned for late August 2026.
The approved initiation regimen is 500 mg once weekly, delivered as two 250 mg autoinjector doses of about 15 seconds each. Leqembi Iqlik is already approved in the US for maintenance at 360 mg once weekly after 18 months of IV or SC treatment, enabling at-home therapy from initiation through maintenance with flexibility to switch between IV and SC administration.
According to BioArctic, sub-studies from the Phase 3 Clarity AD long-term extension showed subcutaneous dosing achieved exposure equivalent to IV, supporting similar efficacy and amyloid removal, with a generally similar safety profile. Injection-related reactions were observed, mostly localized, and systemic reactions were less frequent. An autoinjector acceptability study found 94% of patients and care partners considered the device easy to use with high satisfaction in at-home settings.
BioArctic (Nasdaq Stockholm: B) announced that its partner Eisai presented new data at AAIC 2026 in London showing the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) achieved pharmacokinetic exposure comparable to the approved IV initiation regimen in early Alzheimer's disease.
Once-weekly 500 mg SC-AI was bioequivalent to IV 10 mg/kg every two weeks, with an exposure ratio of 104% (90% CI: 99.1%–109%), and consistent results across body-weight groups, supporting a fixed-dose regimen. Clinical and biomarker outcomes, including amyloid PET, CDR-SB and ARIA-E incidence, were described as driven by lecanemab exposure rather than administration route.
The SC-AI formulation showed a safety profile generally aligned with IV Leqembi, with mostly localized injection reactions, low anti-drug antibody incidence of 1.4% and no neutralizing antibodies. Early clinical practice data from two US centers indicated slower cognitive decline or stable cognition in treated patients, plus high patient and care partner satisfaction, convenience and willingness to recommend treatment.
Barrick Mining Corporation (NYSE:B)(TSX:ABX) will release its Q2 2026 results on Monday, August 10, 2026, at 6:00 AM ET before market open. Management will host a live webcast and presentation at 11:00 AM ET, followed by an analyst Q&A. Presentation materials and a replay will be available on Barrick’s website.
Crawford & Company (NYSE:A) renewed its corporate membership with RISE (Rising Insurance Star Executives), underscoring a commitment to developing early-career insurance professionals. RISE offers mentorship, education, networking and leadership programs that help build future insurance leaders.
Crawford highlights this membership as part of a broader talent strategy that includes Broadspire’s Early Career and Global Technical Services’ Protégé Programs, internships, university partnerships and structured training through Crawford Educational Services.